Table 1

Table 1 a-c: outcomes of DNA testing in polyposis patients

Table 1a. Prevalence gene variants in patients with 1-10 adenomas

	*APC*	*MUTYH* biallelic	Polyposis gene other
Terlouw	0,3% 1/328	1.8% (6/328)	ND
Terlouw > 60 yrs	0/61	0/103	ND
Grover	44/1147 (4%)	19/1147 (1.7%)	ND

1b. Prevalence gene variants in patients with 10-20 adenomas

	*APC*	*MUTYH* biallelic	Polyposis gene other	Hamar-tomateus	MMR	*Other (TP53, CDH1)*
Terlouw	3 /402 (0.7%)	6 /402 (1.5%)	ND	ND	ND	ND
Terlouw >70	0/82	0/82	ND	ND	ND	ND
Stanich	14/1342 (1%)	15/1342 (1.1%)	2/1342 (0.2%)	13/1342 (1%)	41/1342 (3.3%) includes chek2	1 (0.1%)
Stanich 70-80 yrs	1/151 (0.7%)	0/151	0/151		7/151 (4.6%) includes chek2
Stanich >80 yrs	0/39	0/39	0/39		3/93 (7.7%), includes chek2
Grover	50/970 (5%)	37/970 (3.8%)	ND	ND	ND	ND

Table 1c. Prevalence gene variant in patients with 20-100 adenomas

	*APC*	*MUTYH* biallelisch	Polyposis gene other	Hamar-tomatous	MMR	*Other (TP53, CDH1)*
Terlouw	65/712(9%)	82/712 (12%)	ND	ND	ND	ND
Terlouw >70 yrs	0/90	1/90 (1.1%)	ND	ND	ND	ND
Stanich	65/1637 (4%)	73/1673 (4.5%)	1/1673 (0.1%)	40/1673 (2.4%)	19/1637 (1.1%) includes chek2	8/1637 (0.5%)
Stanich >70 yrs	8/297 2.7% (APC and MUTYH combined)	See APC	See APC	2/297 0.7%	11/297 (3.7%) includes chek2	Not specified
Stanich > 80	2/44 4.5% (APC and MUTYH combined)	See APC	See APC	0/44 0%	3/44 6.8% includes chek2	Not specified
Grover	326/3253 (10%)	233/3253 (7%)